Main Results Achieved in 2017
Science, Scientific Production
Total scientific production of the Cancer Research Programme investigators was 177 articles, of which 115 were published in first quartile journals.
Science, Approved Research Projects
Total approved research projects of the Cancer Research Programme investigators was 13. Of the total projects, 5 were financed by ISCIII (Spanish Ministry of Health), the rest of the projects were financed by private funding: Spanish Association of Gastroenterology (1), Departament de Salut (PERIS) (2), Gilead Sciences (1), FEHH (1), Spanish Foundation for Thrombosis and Hemostasis (FETH) (1), Catalan Society of Digestology (1), Spanish Association against Cancer (AECC) (1).
Science, networking activities
The Cancer Research Programme investigators have participated in European and national Research Networks to foster a culture of networking and cooperation. The networks are the following: Spanish Society of Hematology and Hemotherapy (SEHH) (Espinet); Spanish Cooperative Group of Hematological Cytogenetics (GCECGH) (Espinet); Spanish Group of Hematological Cytology (GECH) (Espinet); Spanish Group of Chronic Lymphocytic Leukemia (GELLC) (Espinet); Spanish Group of Myelodysplastic Syndromes (GESMD) (Espinet); Spanish Association of Human Genetics (AEGH) (Espinet); Lymphoma Group of the Spanish Association of Dermatology and Venereology (AEDV) (Espinet); European Cytogeneticists Association (ECA) (Espinet); Splenic B-cell Lymphoma Group (SBLG) (Espinet); Cytogenetic European Quality Assessment (CEQA), Mature B&T Cell Neoplasms (Espinet); European Research Initiative on CLL (ERIC) (Espinet); GEMFIN (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas) (Besses) ; MPNEuronet (http://www.mpneuronet.eu/) (Besses); GELCAB Grup d’Estudi de Limfomes de Catalunya i Balears) (Besses); GELTAMO (Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea) (Besses); ELN (European LeukemiaNet) (Besses); COST Action about Electroporation (Burdío); ITEMAS (ISCIII): Red de Innovación en Tecnologías Médicas y Sanitarias (Burdío); COLONPREV: Screening for Colorectal Cancer in Intermediate-Risk Populations (Andreu); Research Group of PDPCCR – proColon (Andreu), EPoS. European Polyp Surveillance trial group (Andreu); ENEIDA: National Study on Imflamatory Bowel Disease on Genetic and Environmental Determinants (Andreu); Spanish Coordinator, EURECCA Upper GI Working Group ( Manuel Pera); Spanish Rectal Cancer Project; EuroSurg. The European Surgical Research Collaborative; ESCP pan-European snapshot audit. Cohort studies supported by de European Association of Coloproctology (Miguel Pera); RTICC (Albanell, Navarro, Bigas, García de Herreros, Espinet, Espinosa); CIBERONC (Bigas, Abanell).
Phase I trials, an added value
An added value in the Cancer Research Programme is the development of phase I clinical trials, including 'first-in-human' 'firs-in-class', pharmacokinetic and pharmacodynamics trials. During 2017, 4 phase I trials have been started in addition to 53 clinical trials encompassing different phases. The number of phase I trial may be viewed as low but we feel is in the range that allows us to be competitive in terms of recruitment considering our patient referral area.
Technology
During 2017, we have established 18 contracts with industry.
Education
A total of 20 doctoral theses were defended in 2017.
Weekly meetings were held in the programme where PhD students and post-doctoral researchers present their projects and ongoing work.
Monthly meetings were held in the programme where principal investigators from outside of the institution are invited to share the important issues and results in their areas of expertise. Anna Bigas has been coordinating these meetings and an effort has been made to foster the participation of both full time researchers and clinicians.
The programme director J Albanell (UPF professor), and I Tusquets (UAB professor) have coordinated a Master of Translational and Applied Oncology, under the direct support of the UPF Medical Sciences Dean and as part of the multi-university Master programme coordinated by the UB, UAB and UPF.
Expert Opinions
Members of the programme participate in various scientific and medical societies, and are authors of position papers or members of committees establishing recommendation. The programme coordinator is Advisory Board member of the Cancer Director Plan of Catalonia.
Others
- Fernando Burdío:
- Innovation Award MUTUAL MEDICA. Dra. Clara Pañella
- Excellence in surgical research award “Lino Torre”: Dra. Patricia Sánchez
- Joan Albanell
- Scientific Director of the Spanish Breast Cancer Research Group (GEICAM)
- Clinical Coordinator Breast Cancer CIBERONC programme
- Manuel Pera
- Elected Director of the Executive Committee of the International Society for Disease of the Esophagus (ISDE)
- Elected member of the Scientific Committee of the Spanish Association of Surgeons
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es